TrialSignal
Clinical trial intelligence report
Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT07086755
Status
RECRUITING
Phase
Phase 2/3
Sponsor
Bentley J. Bobrow
Executive brief
Investment-Ready Snapshot
This clinical trial evaluates the efficacy and safety of vadadustat in treating hospitalized patients with nonintubated ARDS. The study is sponsored by The University of Texas Health Science Center, Houston, in collaboration with Akebia Therapeutics. It aims to enroll approximately 1,100 participants and is currently recruiting.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT07086755
Indication
Nonintubated Acute Respiratory Distress Syndrome (ARDS)
Modality
small molecule
Target
Nonintubated Acute Respiratory Distress Syndrome (ARDS) due to pathogen-associated lung injury
Intervention
Vadadustat 900mg, Vadadustat 1200mg, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.